CAR T Cell Therapies for ALL and NHL
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, discusses two abstracts being presented at ASH looking at CAR T cell therapies for the treatment of ALL and NHL.
Clinical Pearls
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, discusses two abstracts being presented at ASH looking at CAR T cell therapies for the treatment of ALL and NHL.
- A phase I study will be presented at ASH evaluating CAR T cell therapy directed against CD19 for the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
- Another phase I study evaluated high dose therapy and ASCT followed by CAR T cell therapy directed against CD19 for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Recent Videos
Related Content
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024Article
The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
